Get the Stockscreener App
0.4648
0.04%
-0.0002
Lyell Immunopharma Inc stock is traded at $0.4648, with a volume of 723.82K.
It is down -0.04% in the last 24 hours and down -33.94% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$0.465
Open:
$0.4592
24h Volume:
723.82K
Relative Volume:
0.74
Market Cap:
$137.22M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-0.5884
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-14.12%
1M Performance:
-33.94%
6M Performance:
-61.90%
1Y Performance:
-77.76%
1-Day Range:
$0.44
$0.4966
1-Week Range:
$0.44
$0.568
52-Week Range:
$0.44
$3.145
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.4648 | 137.22M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com India
Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com
Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com South Africa
Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com
Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks
Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat
Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa
Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com
Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock - Yahoo Finance
Chief Financial Officer of Lyell Immunopharma Charles Newton Buys 989% More Shares - simplywall.st
How to interpret Lyell Immunopharma Inc (LYEL)’s stock chart patterns - US Post News
Lyell Immunopharma stock hits 52-week low at $0.51 By Investing.com - Investing.com Australia
Lyell Immunopharma director Richard Klausner purchases $94,942 in stock - Investing.com India
Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock By Investing.com - Investing.com South Africa
Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com - Investing.com Canada
Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com - Investing.com South Africa
Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock - Investing.com India
Lyell Immunopharma CFO Newton purchases $111,620 in common stock - Investing.com India
Lyell Immunopharma stock hits 52-week low at $0.51 - Investing.com India
Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges - TipRanks
HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright - Defense World
H.C. Wainwright maintains Neutral on Lyell Immunopharma stock By Investing.com - Investing.com Australia
Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline - TipRanks
Lyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last year - TipRanks
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
Breakthrough: Lyell's Cancer Therapy Achieves 94% Response Rate Amid Q4 Financial Results - StockTitan
BlackRock, Inc. Reduces Stake in Lyell Immunopharma Inc - GuruFocus.com
Lyell Immunopharma (LYEL) Projected to Post Earnings on Wednesday - MarketBeat
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - The Manila Times
LYELLyell Immunopharma, Inc. Latest Stock News & Market Updates - StockTitan
Cell Therapy Pioneer Lyell to Showcase Cancer Treatment Breakthroughs at Elite Investor Events - StockTitan
What Did We Find About Insider Trading At Lyell Immunopharma Inc (NASDAQ: LYEL)? - Stocks Register
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - MSN
Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners - Simply Wall St
SG Americas Securities LLC Has $75,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Market Recap Check: Lyell Immunopharma Inc (LYEL)’s Negative Finish at 0.57, Up/Down -2.94 - The Dwinnex
Lyell Immunopharma Inc (LYEL) Stock: A Year of Market Fluctuations - The InvestChronicle
Take off with Lyell Immunopharma Inc (LYEL): Get ready for trading - SETE News
LYEL underperforms with a -0.98 decrease in share price - US Post News
Market Momentum Report: Lyell Immunopharma Inc (LYEL)’s Negative Close at 0.58 - The Dwinnex
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):